Cabio Biotech (Wuhan) Co (SHSE:688089) Cash And Cash Equivalents : ¥105.6 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co Cash And Cash Equivalents?

Cabio Biotech (Wuhan) Co's quarterly cash and cash equivalents increased from Mar. 2024 (¥191.77 Mil) to Jun. 2024 (¥203.07 Mil) but then stayed the same from Jun. 2024 (¥203.07 Mil) to Sep. 2024 (¥105.61 Mil).

Cabio Biotech (Wuhan) Co's annual cash and cash equivalents declined from Dec. 2021 (¥664.47 Mil) to Dec. 2022 (¥494.33 Mil) and declined from Dec. 2022 (¥494.33 Mil) to Dec. 2023 (¥239.68 Mil).

Cabio Biotech (Wuhan) Co Cash And Cash Equivalents Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co Cash And Cash Equivalents Chart

Cabio Biotech (Wuhan) Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

844.32

847.32

664.47

494.33

239.68

Cabio Biotech (Wuhan) Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash And Cash Equivalents	Get a 7-Day Free Trial															236.26	239.68	191.77	203.07	105.61

Cabio Biotech (Wuhan) Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Cabio Biotech (Wuhan) Co (SHSE:688089) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Cabio Biotech (Wuhan) Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Cabio Biotech (Wuhan) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 999, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, CHN, 430073

Website

http://www.cabio.cn

Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.

Executives

Xiao Min	senior management
Shang Yun	Core technical personnel
Wang Hua Biao	Directors, senior managers
Geng An Feng	senior management
Du Bin	Director
Yi Hua Rong	senior management
Ma Tao	senior management
Li Xiang Yu	senior management
Wu Yu Jun	Supervisors
Wang Zhi Ming	senior management
Lu Shu Huan	Core technical personnel
Yi De Wei	Director

Cabio Biotech (Wuhan) Co Headlines

No Headlines